A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali

Bulletin of the World Health Organization

Volumn 76, Issue 1, 1998, Pages 63-71

  Perry, R T ^a,b   Plowe, C V ^a,b   Koumare B ^c   Bougoudogo, F ^c   Kotloff, K L ^a,b   Losonsky, G A ^a,b   Wasserman, S S ^a,b   Levine, M M ^b  

^a Center for Vaccine Development

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Institut National de Recherche en Sante Publique Mali   (Mali)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CD4 ANTIGEN; CHOLERA VACCINE; LIVE VACCINE; PLACEBO;

ADULT; ANTIBODY TITER; ARTICLE; CHOLERA; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALI; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; VIBRIO CHOLERAE; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; AFRICA SOUTH OF THE SAHARA; BACTERIAL AND FUNGAL DISEASES; CHOLERA--PREVENTION AND CONTROL; CLINICAL RESEARCH; DEVELOPING COUNTRIES; DISEASES; FRENCH SPEAKING AFRICA; HIV INFECTIONS; INFECTIONS; MALI; RESEARCH METHODOLOGY; RESEARCH REPORT; VACCINES; VIRAL DISEASES; WESTERN AFRICA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHOLERA VACCINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FEVER; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MALE; MALI; MIDDLE AGED; NAUSEA; VIBRIO CHOLERAE; VOMITING;

EID: 0031779825     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Goodgame RW et al. Cholera in Africa: a message for the West. Annals of internal medicine, 1975, 82: 101-106.
2. Glass RI et al. Cholera in Africa: lessons on transmission and control for Latin America. Lancet, 1991, 338: 791-795.
3. Eko FO et al. Epidemiology and spectrum of vibrio diarrheas in the lower cross river basin of Nigeria. Central European journal of public health, 1994, 2: 37-41.
4. Tauxe RV et al. Epidemic cholera in Mali: high mortality and multiple routes of transmission in a famine area. Epidemiology and infection, 1988, 100: 279-289.
5. St. Louis ME et al. Epidemic cholera in West Africa: the role of food handling and high-risk foods. American journal of epidemiology, 1990, 131: 719-728.
6. Goma Epidemiology Group. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994? Lancet, 1995, 345: 339-344.
7. Ramsay S. Cholera vaccination in emergencies. Lancet, 1997, 345: 1630.
8. Swerdlow DL et al. Cholera control among Rwandan refugees in Zaire. Lancet, 1994, 344: 1302-1303.
9. Sack DA. Cholera control. Lancet, 1994, 344: 616-617.
10. Hatch DL et al. Epidemic cholera during refugee resettlement in Malawi. International journal of epidemiology, 1994, 23: 1292-1299.
11. Iijima Y et al. Simultaneous outbreak due to Vibrio cholerae and Shigella dysenteriae in Kenya. Lancet, 1995, 345: 69-70.
12. Levine MM et al. Live oral cholera vaccine: from principle to product. Bulletin of the Institut Pasteur, 1995, 93: 243-253.
13. Levine MM et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet, 1988, 2: 467-470.
14. Tacket CO et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. Journal of infectious diseases, 1992, 166: 837-841.
15. Kotloff KL et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infection and immunity, 1992, 60: 4430-4432.
16. Suharyono et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet, 1992, 340: 689-694.
17. Simanjuntak CH et al. The safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children. Journal of infectious diseases, 1993, 168: 1169-1176.
18. Su-Arehawaratana P et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. Journal of infectious diseases, 1992, 165: 1042-1048.
19. Gotuzzo E et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infection and immunity, 1993, 61: 3994-3997.
20. Lagos R et al. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infection and immunity, 1995, 63: 707-709.
21. Lagos R et al. [Tolerance, immunogenicity, excretion and transmission of the live, attenuated oral cholera vaccine, CVD 103-HgR: double-blind study on Chilean children aged 24-59 months]. Boletín de Medicina del Hospital Infantil de Mexico, 1996, 53: 214-220 (in Spanish).
22. Levine MM et al. Live oral vaccines against cholera: an update. Vaccine, 1993, 11: 207-212.
23. Rey JL et al. HIV seropositivity and cholera in refugee children from Rwanda. AIDS, 1995, 9: 1203-1204.
24. Bourée P et al. Study of an HIV positive, tropical origin population in a refugee center in France. Bulletin de la Société de Pathologie Exotique, 1995, 88: 24-28.
25. Cossa HA et al. Syphilis and HIV infection among displaced pregnant women in rural Mozambique. International journal of sexually transmitted diseases and AIDS, 1994, 5: 117-123.
26. Van Rensburg EJ et al. Prevalence of viral infections in Mozambican refugees in Swaziland. East African medical journal, 1995, 72: 588-590.
27. Wasserman SS et al. Kinetics of the vibriocidal antibody response to live oral cholera vaccines. Vaccine, 1994, 12: 1000-1003.
28. Benenson AS et al. Serological studies in cholera. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bulletin of the World Health Organization, 1968, 38: 277-285.
29. Clements ML et al. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. Journal of infectious diseases, 1982, 145: 465-473.
30. Mosley WH et al. A serological survey for cholera antibodies in rural east Pakistan. I. The distribution of antibody in the control population of a cholera vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bulletin of the World Health Organization, 1968, 38: 327-334.
31. Mosley WH et al. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bulletin of the World Health Organization, 1968, 38: 777-785.
32. Glass RI et al. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. Journal of infectious diseases, 1985, 151: 236-242.
33. Clemens JD et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. Journal of infectious diseases, 1991, 163: 1235-1242.
34. Levine MM et al. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. Journal of clinical microbiology, 1985, 21: 174-179.
35. Kaper JB et al. Cholera. Clinical microbiology reviews, 1995, 8:48-86.
36. Levine MM et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infection and immunity, 1988, 56: 161-167.
37. Mahalanabis D et al. Oral fluid therapy of cholera among Bangladesh refugees. Johns Hopkins medical journal, 1973, 132: 197-205.
38. Siddique AK. Failure of treatment centres to prevent cholera deaths in Goma. Lancet, 1995, 346: 379.
39. Levine MM, Pierce NF. Immunity and vaccine development. In: Barua D, Greenough WB, III, eds. Cholera. New York, Plenum, 1992: 285-327.
40. Clemens JD et al. Field trial of cholera vaccines in Bangladesh: results from three year follow-up. Lancet, 1990, 335: 270-273.
41. Sanchez JL et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet, 1994, 344: 1273-1276.
42. Clemens JD et al. Field trial of oral cholera vaccines in Bangladesh. Lancet, 1986, 2: 124-127.
43. Lewis DJ et al. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS, 1994, 8: 779-785.
44. Huang KL et al. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. Journal of the American Medical Association, 1987, 257: 2047-2050.
45. Carson PJ et al. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. Journal of infectious diseases, 1995, 172: 340-345.
46. Birx DL et al. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. Journal of acquired immune deficiency syndrome, 1991, 4: 188-196.
47. Kroon FP et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS, 1994, 8: 469-476.
48. Janoff EN et al. Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. Journal of infectious diseases, 1988, 158: 983-990.
49. Collier AC et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Annals of internal medicine, 1988, 109: 101-105.
50. Stanley S et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. New England journal of medicine, 1996, 334: 1222-1230.
51. Staprans SI et al. Activation of virus replication after vaccination of HIV-1-infected individuals. Journal of experimental medicine, 1995, 182: 1727-1737.
52. O'Brien WA et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood, 1995, 86: 1082-1089.
53. Glesby MJ et al. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. Journal of infectious diseases, 1996, 174: 1332-1336.
54. Brichacek B et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. Journal of infectious diseases, 1996, 174: 1191-1199.